8-K 1 ohr-8k_022017.htm CURRENT REPORT




Washington, D.C. 20549





Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): February 20, 2017


Ohr Pharmaceutical, Inc.

(Exact Name of Registrant as Specified in Its Charter)


Delaware   333-88480   46-5622433
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)



800 Third Avenue, 11th Floor, New York, NY    10022
(Address of Principal Executive Offices) (Zip Code)


(212) 682-8452

(Registrant's Telephone Number, Including Area Code)


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01 Other Events


On February 21, 2017, Ohr Pharmaceutical, Inc. (the ‘Company”) took actions to suspend activities at its lab facility in San Diego, California where the preclinical research regarding the sustained release platform technology had been conducted. The suspension of preclinical activities at the lab facility will result in a reduction in workforce of approximately 8 positions at the lab facility, which reduction will occur immediately.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 Date: February 22, 2017 By:   /s/ Sam Backenroth
    Sam Backenroth
    Chief Financial Officer